1 min read
Add as a preferred source on Google

CNS Pharmaceuticals Posts $0.24 Q3 Loss Per Share as Cash Reaches $17.2M

Cash and cash equivalents were $17.2 million at Sept. 30, up from $7.2 million at the end of 2025. The company believes its existing cash can fund planned operations beyond 12 months.

A blank financial statement sheet forms two rising planes. / TokenPost.ai
A blank financial statement sheet forms two rising planes. / TokenPost.ai

CNS Pharmaceuticals, Inc. (CNSP) had a third-quarter loss of $0.24 per share, compared with a loss of $5.76 per share in the same quarter a year earlier. The smaller per-share loss came alongside a higher cash balance at Sept. 30, 2026.

Cash and cash equivalents totaled $17.2 million at the end of the third quarter, up from $7.2 million on Dec. 31, 2025.

CNS Pharmaceuticals believes its existing cash resources are sufficient to fund planned operations beyond 12 months from the date its financial statements were issued.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…